The sell-off began early in the session, with the stock opening at $2.76 before sliding to $2.17 by midday. The 28% decline followed the company’s disclosure that it intends to issue up to 5.1 million units, each comprising a single share or pre-funded warrant along with two additional warrants. This dilutive move effectively neutralized the momentum generated by recent corporate milestones.

This aggressive capital raise comes at a critical juncture for the firm. On Thursday, Profusa had reported a strategic collaboration with the Mayo Clinic intended to accelerate the regulatory path for its Lumee oxygen monitoring product. While the partnership aims to streamline commercialization and clinical validation, the immediate prospect of share dilution appears to have dictated the market's reaction.

The Lumee system represents Profusa's core technological push into continuous tissue-oxygen monitoring. Despite the clinical backing of a major healthcare institution, the company's decision to tap equity markets for liquidity has, for now, overshadowed the long-term potential of its product pipeline.